A 15 months, double-Blind, randomized controlled trial comparing 18 weeks of two doses of Omalizumab to placebo to accelerate a symptom-driven Oral immunotherapy schedule in subjects aged 6 to 25 years with Multiple food allergies (BOOM).
A 15 months, double-Blind, randomized controlled trial comparing 18 weeks of two doses of Omalizumab to placebo to accelerate a symptom-driven Oral immunotherapy schedule in subjects aged 6 to 25 years with Multiple food allergies (BOOM).
一项为期 15 个月的双盲随机对照试验，比较了 18 周的两剂奥马珠单抗与安慰剂，以加速 6 至 25 岁多种食物过敏 (BOOM) 受试者的症状驱动口服免疫治疗计划。
批准号：
402372
负责人：
Bgin Philippe
金额：
$19.51万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-03-01 至 2022-03-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Oral immunotherapy (OIT) is a new treatment for food allergy, where allergists administer patients precisely measured amounts of their allergen to progressively deplete antibodies on allergy cells and build their tolerance over time up to a full portion o
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
